IM-21

N/A

Report date: 2025/07/26 20:00:09

Base Information

Drug NameIM-21

Drug Alias NameIM21 CAR-T cellsIM21IM-21

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulators

TargetsTumor necrosis factor ligand superfamily member 13

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesImunopharm Technology Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImunopharm Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A